Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF | R&D Systems 156-B7-100 product information

product summary

company name :

R&D Systems

product type :

protein

product name :

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

catalog :

156-B7-100

quantity :

100 ug (also 1 mg)

price :

408 USD

more info or order :

R&D Systems product webpage

citations: 26

Reference
Rattanapisit K, Bulaon C, Strasser R, Sun H, Phoolcharoen W. In vitro and in vivo studies of plant-produced Atezolizumab as a potential immunotherapeutic antibody. Sci Rep. 2023;13:14146 pubmed publisher
Lorenzini T, Cadilha B, Obeck H, Benmebarek M, M xe4 rkl F, Michaelides S, et al. Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy. Br J Cancer. 2023;129:696-705 pubmed publisher
Coulet M, Lachkar S, Leduc M, Trombe M, Gouveia Z, Perez F, et al. Identification of Small Molecules Affecting the Secretion of Therapeutic Antibodies with the Retention Using Selective Hook (RUSH) System. Cells. 2023;12: pubmed publisher
Munoz O, Banga R, Schelling R, Procopio F, Mastrangelo A, Nortier P, et al. Active PD-L1 incorporation within HIV virions functionally impairs T follicular helper cells. PLoS Pathog. 2022;18:e1010673 pubmed publisher
Gao Q, Wang S, Li F, Lian J, Cheng S, Yue D, et al. High Mobility Group Protein B1 Decreases Surface Localization of PD-1 to Augment T-cell Activation. Cancer Immunol Res. 2022;10:844-855 pubmed publisher
Curnock A, Bossi G, Kumaran J, Bawden L, Figueiredo R, Tawar R, et al. Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors. JCI Insight. 2021;6: pubmed publisher
Bhaskaran N, Schneider E, Faddoul F, Paes da Silva A, Asaad R, Talla A, et al. Oral immune dysfunction is associated with the expansion of FOXP3+PD-1+Amphiregulin+ T cells during HIV infection. Nat Commun. 2021;12:5143 pubmed publisher
Mao C, Wang S, Su Y, Tseng S, He L, Wu A, et al. Protein detection in blood with single-molecule imaging. Sci Adv. 2021;7: pubmed publisher
Vetrei C, Passariello M, Froechlich G, Rapuano Lembo R, Zambrano N, De Lorenzo C. Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments. Cancers (Basel). 2021;13: pubmed publisher
Ogishi M, Yang R, Aytekin C, Langlais D, Bourgey M, Khan T, et al. Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child. Nat Med. 2021;: pubmed publisher
Huetter J, Gritzan U, Gutcher I, Doecke W, Luetke Eversloh M, Golfier S, et al. Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2). Cancer Immunol Res. 2020;8:895-911 pubmed publisher
Sun L, Li C, Chung E, Yang R, Kim Y, Park A, et al. Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity. Cancer Res. 2020;80:2298-2310 pubmed publisher
Cembrola B, Ruzza V, Troise F, Esposito M, Sasso E, Cafaro V, et al. Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries. Biomed Res Int. 2019;2019:6051870 pubmed publisher
Carpenter K, Valfort A, Steinauer N, Chatterjee A, Abuirqeba S, Majidi S, et al. LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer. Sci Rep. 2019;9:19530 pubmed publisher
Fu W, Lei C, Liu S, Cui Y, Wang C, Qian K, et al. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nat Commun. 2019;10:4355 pubmed publisher
Fierle J, Abram Saliba J, Brioschi M, deTiani M, Coukos G, Dunn S. Integrating SpyCatcher/SpyTag covalent fusion technology into phage display workflows for rapid antibody discovery. Sci Rep. 2019;9:12815 pubmed publisher
Osa A, Uenami T, Koyama S, Fujimoto K, Okuzaki D, Takimoto T, et al. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight. 2018;3: pubmed publisher
Vogl U, Ohler L, Rasic M, Frischer J, Modak M, Stockl J. Evaluation of Prognostic Immune Signatures in Patients with Breast, Colorectal and Pancreatic Cancer Receiving Chemotherapy. Anticancer Res. 2017;37:1947-1955 pubmed
Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, et al. Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice. Mol Cancer Ther. 2017;16:861-870 pubmed publisher
Li J, Shayan G, Avery L, Jie H, Gildener Leapman N, Schmitt N, et al. Tumor-infiltrating Tim-3+ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk. Oncoimmunology. 2016;5:e1200778 pubmed
Liu X, Wu X, Cao S, Harrington S, Yin P, Mansfield A, et al. B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8+ T cells. Sci Rep. 2016;6:36722 pubmed publisher
Li J, Jie H, Lei Y, Gildener Leapman N, Trivedi S, Green T, et al. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res. 2015;75:508-518 pubmed publisher
Melendreras S, MartÃnez Camblor P, MenÃ©ndez A, Bravo Mendoza C, GonzÃ¡lez Vidal A, Coto E, et al. Soluble co-signaling molecules predict long-term graft outcome in kidney-transplanted patients. PLoS ONE. 2014;9:e113396 pubmed publisher
Chinnadurai R, Copland I, Patel S, Galipeau J. IDO-independent suppression of T cell effector function by IFN-?-licensed human mesenchymal stromal cells. J Immunol. 2014;192:1491-501 pubmed publisher
Steidl C, Shah S, Woolcock B, Rui L, Kawahara M, Farinha P, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011;471:377-81 pubmed publisher
Wan B, Nie H, Liu A, Feng G, He D, Xu R, et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol. 2006;177:8844-50 pubmed

image

image 1 :

Graph showing bioactivity of Human PD-L1 protein (B7-H1 protein)

product information

brand :

R&D Systems, a Bio-Techne Brand

catalog number base :

156-B7

SKU :

156-B7-100

product name :

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Description :

The Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF from R&D Systems is derived from NS0. The Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF has been validated for the following applications: Bioactivity.

target :

PD-L1/B7-H1

category :

Proteins and Enzymes

unit size :

100 ug (also 1 mg)

buffer :

Lyophilized from a 0.2 µm filtered solution in PBS and NaCl.

conjugate :

Unconjugated

purity :

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

species :

Human

observed molecular weight :

70-75 kDa, reducing conditions

theoretical molecular weight :

52 kDa (monomer)

gene symbol :

CD274

details of functionality :

Measured by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocytes. The ED50 for this effect is 0.075-0.75 µg/mL.

endotoxin note :

<0.01 EU per 1 µg of the protein by the LAL method.

accessionNumbers :

Q9NZQ7

applications :

Bioactivity

source :

NS0-derived Recombinant Human PD-L1/B7-H1 Fc Chimera Protein

extended description :

Analyzed by SEC-MALS

USD :

408 USD

product details :

Analyzed by SEC-MALS

alt names :

Avelumab, B7-H, B7H1, B7-H1, B7H1PDCD1L1, CD274, CD274 antigenMGC142294, CD274 molecule, PDCD1L1, PDCD1LG1, PDCD1LG1MGC142296, PDL1, PD-L1, PD-L1B7 homolog 1, PDL1PDCD1 ligand 1, programmed cell death 1 ligand 1, Programmed death ligand 1

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

more info or order :

R&D Systems product webpage